Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Leukemia

• Publication date

  2011-11-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/leu.2011.298PMID 22033490
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F

  2011cited by this paper
• The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.

  2011cited by this paper
• Isolated del(5q) in myeloid malignancies: Clinicopathologic and molecular features in 143 consecutive patients

  2011cited by this paper
• 14 Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS (IWG-PM)

  2011cited by this paper
• The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia

  2011cited by this paper
• IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis

  2011cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2010cited by this paper
• Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.

  2010cited by this paper
• Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.

  2010cited by this paper
• IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis

  2010cited by this paper
• IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia.

  2010cited by this paper
• Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

  2010cited by this paper
• IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.

  2010cited by this paper
• Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.

  2010cited by this paper
• IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis

  2010cited by this paper
• IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

  2010cited by this paper
• Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms

  2010cited by this paper
• IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

  2010cited by this paper
• The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

  2010cited by this paper
• Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q)

  2010cited by this paper
• The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status.

  2010cited by this paper
• JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival

  2010cited by this paper
• Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

  2010cited by this paper
• Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

  2010cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2009cited by this paper
• The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

  2009cited by this paper
• Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α

  2009cited by this paper
• Recurring mutations found by sequencing an acute myeloid leukemia genome.

  2009cited by this paper
• Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

  2009cited by this paper
• Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

  2008cited by this paper
• An Integrated Genomic Analysis of Human Glioblastoma Multiforme

  2008cited by this paper
• MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.

  2006cited by this paper

• Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies

  2025cites this paper
• Impact of Epigenetic Mutations in Chronic Myelomonocytic Leukemia

  2025cites this paper
• Progress in the Genetics of Myelodysplastic Syndromes with a Latin American Perspective

  2025cites this paper
• Inflammatory disorders in IDH‐mutated myeloid neoplasms: Characteristics and response to IDH inhibitors

  2025cites this paper
• NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.

  2025cites this paper
• Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib.

  2025cites this paper
• Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions

  2024cites this paper
• A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms

  2024cites this paper
• Advances in the management of higher-risk myelodysplastic syndromes: future prospects

  2024cites this paper
• This differentiation block will not stand, man: ivosidenib for MDS

  2024cites this paper
• Deciphering the Multifaceted Roles and Clinical Implications of 2-Hydroxyglutarate in Cancer.

  2024cites this paper
• The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches

  2023cites this paper
• Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia

  2023cites this paper
• Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia

  2023cites this paper
• The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia

  2023cites this paper
• Epidemiology and Pathogenesis of Myelodysplastic Syndrome

  2023cites this paper
• IDH2 mutations in acute myeloid leukemia

  2023cites this paper
• Myelodysplastic Syndrome: Diagnosis and Screening

  2022cites this paper
• IDH mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy

  2022cites this paper
• Patterns of use of biological and genetic markers for chronic lymphocytic leukemia and acute myeloid leukemia in Puerto Rico

  2022cites this paper
• MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors

  2022cites this paper
• NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.

  2022cites this paper
• Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia

  2022cites this paper
• A phase 1 study of IDH305 in patients with IDH1^R132-mutant acute myeloid leukemia or myelodysplastic syndrome

  2022cites this paper
• Molecular and genomic landscapes in secondary & therapy related acute myeloid leukemia.

  2021cites this paper
• Asian Population Is More Prone to Develop High-Risk Myelodysplastic Syndrome, Concordantly with Their Propensity to Exhibit High-Risk Cytogenetic Aberrations

  2021cites this paper
• Synthesis and Evaluation of 3-(Indol-3-yl)-4-(Pyrazolo[3,4-c]Pyridazin-3-yl)-Maleimides as Potent Mutant Isocitrate Dehydrogenase-1 Inhibitors

  2021cites this paper
• Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes

  2021cites this paper
• Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence

  2021cites this paper
• Mitochondria and Their Relationship with Common Genetic Abnormalities in Hematologic Malignancies

  2021cites this paper
• Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia

  2021cites this paper
• The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication?

  2021cites this paper
• Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape

  2021cites this paper
• BLCTT_A_236446 41..54

  2021cites this paper
• The Evolving Landscape of Myelodysplastic Syndrome Prognostication

  2020cites this paper
• Isocitrate Dehydrogenase 2 Inhibitors for the treatment of Hematologic Malignancies: Advances and Future Opportunities.

  2020cites this paper
• IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis.

  2020cites this paper
• Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation

  2020cites this paper
• Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias

  2020cites this paper
• Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges

  2020cites this paper
• Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia

  2020cites this paper
• New Agents in the Treatment of Acute Myeloid Leukemia

  2020cites this paper
• Dysregulation of the TET family of epigenetic regulators in hematopoietic malignancies.

  2019cites this paper
• Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment

  2019cites this paper
• High expression of PIM2 induces HSC proliferation in myelodysplastic syndromes via the IDH1/HIF1-α signaling pathway

  2019cites this paper
• Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications

  2019cites this paper
• Changes in IDH2, TET2 and KDM2B Gene Expression After Treatment With Classic Chemotherapeutic Agents and Decitabine in Myelogenous Leukemia Cell Lines

  2019cites this paper
• Treatment of myelodysplastic syndrome in the era of next‐generation sequencing

  2019cites this paper
• Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers

  2019cites this paper
• Mutation Status in Myeloid Malignancies Informs Clinical Insight

  2019cites this paper
• Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms: A Report of the Association for Molecular Pathology.

  2018cites this paper
• Reduced hydroxymethylation characterizes medulloblastoma while TET and IDH genes are differentially expressed within molecular subgroups

  2018cites this paper
• Perfil de mutações em pacientes com citopenia clonal de significado indeterminado, síndrome mielodisplásica e neoplasias mielóides relacionadas / Mutations profile in patients with clonal cytopenia of undetermined significance, myelodisplastic syndromes and related neoplasms

  2018cites this paper
• Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes

  2018cites this paper
• The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome

  2018cites this paper
• Diagnosis and Prognosis: Molecular

  2018cites this paper
• The Progress of Next Generation Sequencing in the Assessment of Myeloid Malignancies

  2018cites this paper
• The Progress of Next Generation Sequencing in Assessment of Myeloid Malinancies

  2018cites this paper
• Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes

  2018cites this paper
• Imaging and Metabolism

  2017cites this paper
• Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms

  2017cites this paper
• Individual risk assessment in MDS in the era of genomic medicine.

  2017cites this paper
• Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms

  2017cites this paper
• Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends

  2017cites this paper
• Targeted next‐generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS‐R

  2017cites this paper
• Roles of the Immune Cytokine Environment on Clonal Growth of Murine and Human Tet2 Mutant Bone Marrow Progenitors: Implications for Myelodysplastic Syndromes

  2017cites this paper
• Characterization of TP53 mutations in low‐grade myelodysplastic syndromes and myelodysplastic syndromes with a non‐complex karyotype

  2017cites this paper
• IDH mutations associated impact on related cancer epidemiology and subsequent effect toward HIF-1α.

  2017cites this paper
• Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight

  2017cites this paper
• IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes

  2017cites this paper
• NORMOCELLULAR BONE MARROW WITH MATURING TRILINEAGE HEMATOPOIESIS AND MOLECULAR EVIDENCE OF CLONAL HEMATOPOIESIS

  2017cites this paper
• Glioblastoma and acute myeloid leukemia: malignancies with striking similarities

  2017cites this paper
• Association between Transfusion Status and Overall Survival in Patients with Myelodysplastic Syndromes: A Systematic Literature Review and Meta-Analysis

  2016cites this paper
• Novel therapeutic strategies in myelodysplastic syndromes: do molecular genetics help?

  2016influential citation
• IDH mutations in cancer and progress toward development of targeted therapeutics.

  2016cites this paper
• Isocitrate Dehydrogenase Mutations in Human Cancers: Physiopathologic Mechanisms and Therapeutic Targeting

  2016cites this paper
• Impact pronostique de la maladie résiduelle par quantification des mutations d'IDH1/2 par PCR digitale dans les leucémies aiguës myéloïdes incluses dans les protocoles alfa-0701 et 0702

  2016cites this paper
• Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes.

  2016cites this paper
• Somatic Mutations in Myelodysplastic Syndrome Patients in the Context of Allogeneic Stem Cell Transplantation

  2016cites this paper
• Isocitrate dehydrogenase mutations in myeloid malignancies

  2016cites this paper
• IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives

  2016cites this paper
• The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors.

  2016cites this paper
• Epigenetic regulators and their impact on therapy in acute myeloid leukemia

  2016cites this paper
• Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

  2016cites this paper
• Title Molecular and Cellular Mechanisms of MyelodysplasticSyndrome : Implications on Targeted Therapy

  2016cites this paper
• Myelodysplastic syndromes: Contemporary review and how we treat

  2016cites this paper
• Beyond the Oncogene Revolution: Four New Ways to Combat Cancer.

  2016cites this paper
• Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia

  2016cites this paper
• Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy

  2016cites this paper
• Roles of IDH1/2 and TET2 mutations in myeloid disorders

  2016cites this paper
• Metabolomic comparison between cells over‐expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism

  2015cites this paper
• The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.

  2015cites this paper
• 5-Hydroxymethylcytosine: An epigenetic mark frequently deregulated in cancer.

  2015cites this paper
• 5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy.

  2015cites this paper
• TET family proteins: oxidation activity, interacting molecules, and functions in diseases.

  2015cites this paper
• Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders.

  2015cites this paper
• IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression

  2015cites this paper
• Digging deep into “dirty” drugs – modulation of the methylation machinery

  2015cites this paper
• Mutation Analysis of IDH1/2 Genes in Unselected De novo Acute Myeloid Leukaemia Patients in India - Identification of A Novel IDH2 Mutation.

  2015cites this paper
• Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia

  2015cites this paper